ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. Using our proprietary target discovery engine, EpiSelect™, we can predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). We have offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Our differentiated approach leverages the accuracy of computational modeling to enable the generation of therapeutic antibodies that are highly selective for toxic misfolded proteins and not their normal, physiological forms.
Featured Potential Advantages:
We are leveraging our patented technology to build a product candidate portfolio of therapeutic antibodies, vaccines, and diagnostics to combat neurodegenerative and other misfolded protein diseases like AD, MSA and ALS. Our therapeutic development programs target the biological cause of these diseases - toxic misfolded forms of proteins.
View Our Pipeline Programs